Microbot Medical Inc. Files S-1 Registration Statement

TL;DR

<b>Microbot Medical Inc. has filed an S-1 registration statement with the SEC on February 20, 2024.</b>

AI Summary

Microbot Medical Inc. (MBOT) filed a IPO Registration (S-1) with the SEC on February 20, 2024. Microbot Medical Inc. has filed an S-1 registration statement with the SEC. The filing is dated February 20, 2024. The company's principal executive offices are located in Hingham, MA. Microbot Medical Inc. was formerly known as STEMCELLS INC and CYTOTHERAPEUTICS INC/DE. The company operates in the Surgical & Medical Instruments & Apparatus industry.

Why It Matters

For investors and stakeholders tracking Microbot Medical Inc., this filing contains several important signals. This S-1 filing indicates potential future equity offerings or significant corporate actions by Microbot Medical Inc., which could impact its capital structure and shareholder value. The filing provides updated financial and business information, offering insights into the company's current performance and strategic direction for investors and analysts.

Risk Assessment

Risk Level: low — Microbot Medical Inc. shows low risk based on this filing. The filing is an S-1, which is a standard registration statement for potential securities offerings and does not inherently indicate immediate financial distress or significant positive developments.

Analyst Insight

Monitor future filings from Microbot Medical Inc. for details on any proposed securities offerings or significant business updates stemming from this S-1 registration.

Key Numbers

• 2024-02-20 — Filing Date (Date the S-1 registration statement was filed.)
• 0001493152-24-007226 — Accession Number (Unique identifier for the SEC filing.)
• 333-277190 — SEC File Number (SEC file number associated with the registration.)
• 24654092 — Film Number (Film number for the filing.)

Key Players & Entities

• Microbot Medical Inc. (company) — Filer of the S-1 registration statement.
• STEMCELLS INC (company) — Former name of Microbot Medical Inc.
• CYTOTHERAPEUTICS INC/DE (company) — Former name of Microbot Medical Inc.
• Hingham, MA (location) — Location of Microbot Medical Inc.'s business address.

FAQ

Industry Context

Microbot Medical Inc. operates within the medical instruments and apparatus sector, specifically focusing on surgical applications.

Regulatory Implications

The S-1 filing is a standard requirement under the Securities Act of 1933 for companies planning to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for details on the purpose of the registration (e.g., primary offering, secondary offering).
2. Analyze any disclosed financial statements and business descriptions for insights into the company's operational status.
3. Track subsequent SEC filings (e.g., 424B filings) that will provide details on the terms and pricing of any securities offered.

Key Dates

• 2024-02-20: S-1 Filing — Indicates potential future equity offerings or significant corporate actions.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing to compare it against for changes in financial or business information.

Key Financial Figures

• $0.01 — o 1,005,965 shares of our common stock, $0.01 par value per share, representing share
• $1.29 — stock on the Nasdaq Capital Market was $1.29. Investing in our common stock involv
• $6.75 million — Agreement and return of the Plaintiffs' $6.75 million purchase price with respect to the 2017
• $2,154,000 — ement Agreement, we paid the Plaintiffs $2,154,000 (the "Total Settlement Amount"), consis
• $1,100,000 — ent covered by our insurance carrier of $1,100,000 and 1,005,965 shares of restricted comm
• $1,054,000 — ated pursuant to the following formula: $1,054,000/[closing price of common stock on the E
• $2.20 — 's Common Stock at an exercise price of $2.20 per share, issued on October 25, 2022,
• $2.075 — 's Common Stock at an exercise price of $2.075 per share, issued on June 6, 2023, and
• $3.19 — 's Common Stock at an exercise price of $3.19 per share issued on June 26, 2023 (the
• $1.62 — Stock, at a reduced exercised price of $1.62 per share, in consideration for the Com
• $1.50 — 's Common Stock at an exercise price of $1.50 per share. The Inducement Investment Op
• $2.73 million — s from the transaction of approximately $2.73 million. The Company engaged H.C. Wainwright
• $60,000 — tions. The Company also paid Wainwright $60,000 for non-accountable expenses, and $15,9
• $15,950 — 0,000 for non-accountable expenses, and $15,950 for clearing fees. The Company also agr
• $2.025 — s except for an exercise price equal to $2.025 per share. Further, pursuant to the Eng

Filing Documents

• forms-1.htm (S-1) — 2488KB
• ex5-1.htm (EX-5.1) — 15KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 48KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• forms-1_003.jpg (GRAPHIC) — 12KB
• forms-1_002.jpg (GRAPHIC) — 52KB
• ex5-1_001.jpg (GRAPHIC) — 23KB
• 0001493152-24-007226.txt (&nbsp;) — 8781KB
• mbot-20230930.xsd (EX-101.SCH) — 53KB
• mbot-20230930_cal.xml (EX-101.CAL) — 66KB
• mbot-20230930_def.xml (EX-101.DEF) — 222KB
• mbot-20230930_lab.xml (EX-101.LAB) — 367KB
• mbot-20230930_pre.xml (EX-101.PRE) — 302KB
• forms-1_htm.xml (XML) — 1450KB

USE OF PROCEEDS

USE OF PROCEEDS 30 MARKET FOR COMMON STOCK 30 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 30

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 31

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36

BUSINESS

BUSINESS 37 BOARD OF DIRECTORS AND MANAGEMENT 53

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 59 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 65

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 66 SELLING STOCKHOLDERS 67 PLAN OF DISTRIBUTION 68

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 69 LEGAL MATTERS 73 EXPERTS 73 WHERE YOU CAN FIND MORE INFORMATION 73

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information that we have provided in this prospectus and any prospectus supplement that we may authorize to be provided to you. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any prospectus supplement that we may authorize to be provided to you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus and any prospectus supplement is accurate only as of the date on the cover of the document, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We urge you to carefully read this prospectus and any prospectus supplement, together with the information as described under the heading "Where You Can Find More Information." Unless the context indicates otherwise, as used in this prospectus, the terms "we," "us," "our," the "Company" and "Microbot" refer to Microbot Medical Inc., including our directly and indirectly wholly owned subsidiary. Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Medical Ltd., an Israeli corporation ("Microbot Israel") which became a wholly-owned subsidiary of the Company on November 28, 2016. We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including LIBERTY . All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective

View Full Filing

View this S-1 filing on SEC EDGAR